NCT01843387

Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Mesoblast, Ltd. · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The study investigates the safety, tolerability and efficacy of a single intravenous infusion of two doses of mesenchymal precursor cells versus placebo in subjects with diabetic nephropathy and type 2 diabetes.

Detailed description

This study is taking place in Melbourne, Australia.

Conditions

• Diabetic Nephropathy
• Type 2 Diabetes

Interventions

Type	Name	Description
BIOLOGICAL	Mesenchymal Precursor Cells (MPCs)	Single Intravenous Infusion of MPCs Dose 1 or Placebo
BIOLOGICAL	Mesenchymal Precursor Cells (MPCs)	Single Intravenous Infusion of MPCs Dose 2 or Placebo

Timeline

• Start date: 2013-07-01
• Primary completion: 2014-09-01
• Completion: 2015-09-01
• First posted: 2013-04-30
• Last updated: 2016-10-14

Locations

2 sites across 1 country: Australia